Casado JL - Search Results

1

Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End.

Casado JL. Casado JL. AIDS Rev. 2016 Apr-Jun;18(2):59-68. AIDS Rev. 2016. PMID: 27230467 Review.

2

Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.

Casado JL, Perez-Elías MJ, Antela A, Sabido R, Martí-Belda P, Dronda F, Blazquez J, Quereda C. Casado JL, et al. AIDS. 1998 Jul 30;12(11):F131-5. doi: 10.1097/00002030-199811000-00005. AIDS. 1998. PMID: 9708403

3

Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.

Dronda F, Casado JL, Moreno S, Hertogs K, García-Arata I, Antela A, Pérez-Elías MJ, Ruiz L, Larder B; NELSANE Study. Dronda F, et al. Among authors: casado jl. AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):211-5. doi: 10.1089/088922201750063124. AIDS Res Hum Retroviruses. 2001. PMID: 11177403

4

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.

Pérez-Elías MJ, Moreno S, Gutiérrez C, López D, Abraira V, Moreno A, Dronda F, Casado JL, Antela A, Rodríguez MA. Pérez-Elías MJ, et al. Among authors: casado jl. AIDS. 2005 Apr 29;19(7):695-8. doi: 10.1097/01.aids.0000166092.39317.42. AIDS. 2005. PMID: 15821395 Clinical Trial.

5

Observational study to evaluate clinical outcomes after first-line efavirenz-or lopinavir-ritonavir-based HAART in treatment-naive patients.

Pérez-Elías MJ, Moreno A, Casado JL, Dronda F, Antela A, López D, Quereda C, Navas E, Hermida JM, Del Sol E, Moreno S. Pérez-Elías MJ, et al. Among authors: casado jl. J Int Assoc Physicians AIDS Care (Chic). 2009 Sep-Oct;8(5):308-13. doi: 10.1177/1545109709343965. Epub 2009 Aug 31. J Int Assoc Physicians AIDS Care (Chic). 2009. PMID: 19721095

6

Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine.

Casado JL. Casado JL. AIDS Rev. 2013 Jul-Sep;15(3):139-45. AIDS Rev. 2013. PMID: 24002197 Review.

7

Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients.

Casado JL, Bañon S, Andrés R, Perez-Elías MJ, Moreno A, Moreno S. Casado JL, et al. Osteoporos Int. 2014 Mar;25(3):1071-9. doi: 10.1007/s00198-013-2506-3. Epub 2013 Sep 21. Osteoporos Int. 2014. PMID: 24057480

8

Recent advances in rilpivirine: new data and promising treatment option.

Casado JL, Bañón S. Casado JL, et al. AIDS Rev. 2014 Jul-Sep;16(3):172-81. AIDS Rev. 2014. PMID: 25221991 Review.

9

Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity.

Casado JL, Santiuste C, Vivancos MJ, Monsalvo M, Moreno A, Perez-Elías MJ, Del Rey JM, Moreno S. Casado JL, et al. HIV Med. 2018 Jun 22. doi: 10.1111/hiv.12630. Online ahead of print. HIV Med. 2018. PMID: 29932293 Free article.

10

Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavir.

Fontecha M, Monsalvo M, Rodriguez-Sagrado MA, Vivancos MJ, Moreno A, Casado JL. Fontecha M, et al. Among authors: casado jl. Infect Dis (Lond). 2019 Apr;51(4):293-298. doi: 10.1080/23744235.2018.1554908. Epub 2019 Feb 7. Infect Dis (Lond). 2019. PMID: 30729868

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

279 results

Search Page